Kornimate/medical-research-clean huggingface dataset:
enhanced community first responder system evaluation in singapore

Conditions: Out-Of-Hospital Cardiac Arrest

Summary: the rise in out-of-hospital cardiac arrest (ohca) cases in singapore highlights the need for effective bystander cardiopulmonary resuscitation (bcpr). despite many lay responders performing cpr, survival rates with good neurological outcomes have not significantly improved, prompting research into the quality of cpr as a critical factor. the study by gallagher ej et al. showed a significant survival improvement with high-quality cpr. to address this, the unit of pre-hospital and emergency research (upec) trained thousands of community first responders (cfrs) in simplified cpr techniques using hands-only and da-cpr methods. a significant innovation is the cprcard®, developed by laerdal in norway, which offers real-time feedback on the quality of chest compressions. however, only 36% of cfrs using the cprcard® achieved the desired compression standards, indicating room for improvement. the study proposes enhancing cfr support with information communication technology (ict), enabling two-way audio and one-way video communication between cfrs and dispatchers. this aims to reduce stress among responders, increase their willingness to engage with ohca alerts, and improve cpr quality. the clinical trial in singapore will compare the current system against the enhanced cfr support system (ecss), focusing on the real-time relay of cpr performance data, communication ease, and implementation factors. the high-quality cfr and ohca registries in singapore provide a robust setting for this research, aiming to enhance cpr delivery and improve ohca outcomes through technology and real-time support.


Eligibility criteria:
inclusion criteria: * 18 years old and above * scdf registered cfrs * trial dispatchers with an active account of myresponder® app on their mobile phones exclusion criteria: * the cfrs who are pregnant * experiencing any serious physical conditions * mental health conditions

Keywords: cardiopulmonary resuscitation bystander cpr community first responder cprcard tcpr link
study of oral weekly gs-1720 and gs-4182 versus biktarvy in people with hiv-1 who are virologically suppressed

Conditions: HIV-1-Infection

Summary: the goal of this clinical study is to learn more about the experimental drugs gs-1720 and gs-4182; to compare the combination of gs-1720 and gs-4182 with the current standard-of-care treatment bictegravir/emtricitabine/tenofovir alafenamide (b/f/taf, bvy), to see if the combination of gs-1720 and gs-4182 is safe and if it works for treating human immunodeficiency virus type 1 (hiv-1) infection. this study has two phases: phase 2 and phase 3. the primary objectives of this study are: phase 2: to evaluate the efficacy of switching to oral weekly gs-1720 in combination with gs-4182 versus continuing bvy in virologically suppressed people with hiv-1 (pwh) at week 24. phase 3: to evaluate the efficacy of switching to oral weekly gs-1720/gs-4182 fixed-dose combination (fdc) tablet regimen versus continuing bvy in virologically suppressed pwh at week 48.


Eligibility criteria:
key inclusion criteria: * documented plasma hiv-1 rna \< 50 copies/ml for ≥ 24 weeks before and at screening. * receiving bvy for ≥ 24 weeks prior to screening. key exclusion criteria: * prior use of, or exposure to len, gs-1720, or gs-4182. * history of virologic failure while on an integrase strand-transfer inhibitor (insti)-based regimen. * documented integrase strand-transfer inhibitor (insti) resistance, specifically, resistance-associated mutations (rams) e92g/q, g118r, f121y, y143c/h/r, s147g, q148h/k/r, n155h/s, or r263k in the integrase gene. * prior use of any long-acting (la) parenteral antiretrovirals (arv) such as monoclonal antibodies (mabs) or broadly neutralizing antibodies (bnabs) targeting hiv-1, injectable cabotegravir (including oral cabotegravir lead-in), or injectable rilpivirine. * any of the following laboratory values at screening: * clusters of differentiation 4 (cd4) cell count \< 200 cells/mm\^3 at screening * glomerular filtration rate \< 60 ml/min according to the modification of diet in renal disease formula * hepatic transaminases (aspartate aminotransferase (ast) and alanine aminotransferase (alt) \> 1.5 × upper limit of normal (uln) * direct bilirubin \> 1.5 × uln * platelets count \< 50,000 cells/mm\^3 * hemoglobin \< 8.0 g/dl * active or occult hepatitis b virus (hbv) infection. * active hepatitis c virus (hcv). note: other protocol defined inclusion/exclusion criteria may apply.
study of gefapixant (mk-7264) in acute cough for participants with induced viral upper respiratory tract infection (urti) (mk-7264-013)

Conditions: Acute Cough

Summary: the purpose of the study is to evaluate the efficacy, safety, and tolerability of gefapixant (mk-7264) in adult participants with induced viral upper respiratory tract infections (urti).


Eligibility criteria:
inclusion criteria: * in good general health * susceptible to human rhinovirus type 16 (hrv-16) * male or non-pregnant and non-breast feeding female * if female of reproductive potential, agrees to use 1 form of acceptable birth control exclusion criteria: * donated blood within 56 days or donated plasma within 7 days prior to dosing * history of significant multiple and/or severe allergies * recent history of respiratory tract infection * history of cancer * body mass index \<18 kg/m\^2 or ≥40 kg/m\^2 * history of major surgery or loss of 1 unit of blood * history of allergic reaction to sulfonamides * received medications within 14 days prior to randomization * significantly abnormal laboratory tests at screening * current smoker, smoked within 5 years of screening, or significant past smoking history * history of alcohol or drug abuse
neurofeedback intervention for preclinical alzheimer's disease

Conditions: Alzheimer Disease; Subjective Cognitive Decline; Neurofeedback; Electroencephalogram

Summary: alzheimer's disease (ad) is the most common form of neurodegenerative disorders leading to dementia. currently, there has been no effective pharmacologic therapy for this disease. electroencephalogram-based neurofeedback is considered as a potentially treatment strategy. in this project, the investigators aim to investigate the effectiveness of neurofeedback therapy on cognition for individuals with subjective cognitive decline (scd). participants will receive electroencephalogram-based neurofeedback therapy once a day for successive five days. then, the investigators will evaluate the changes of memory function between baseline and post-therapy visits.

currently, there has been no effective therapy for alzheimer's disease (ad). electroencephalogram-based neurofeedback is now considered as a potentially intervention and may positively affect cognitive function for patients with ad. however, there are few existing studies involving the role of neurofeedback on cognition for subjective cognitive decline (scd). fifty participants with scd will be recruited in this clinical trial. at baseline, neuropsychological tests are conducted. participants will receive electroencephalogram-based neurofeedback therapy once a day for successive five days. after that, the investigators will evaluate the changes of memory measures, which is the primary outcome.

Eligibility criteria:
inclusion criteria: * 50-79 years old, right-handed and mandarin-speaking subjects; * self-experienced persistent decline in cognitive capacity in comparison with a previously normal status and unrelated to an acute event; * normal age-adjusted, gender-adjusted and education-adjusted performance on standardised cognitive tests; * concerns (worries) associated with memory complaint; * failure to meet the criteria for mci or dementia exclusion criteria: * a history of stroke; * major depression (hamilton depression rating scale score \> 24 points); * other central nervous system diseases that may cause cognitive impairment, such as parkinson's disease, tumors, encephalitis and epilepsy; * cognitive impairment caused by traumatic brain injury; * systemic diseases, such as thyroid dysfunction, syphilis and hiv; * a history of psychosis or congenital mental growth retardation.

Keywords: subjective cognitive decline intervention neurofeedback
effectiveness of video consultations in type 1 diabetes patients treated with insulin pumps in the outpatient clinic

Conditions: Telemedicine; Insulin Dependent Diabetes Mellitus 1

Summary: telemedicine is a solution to overcome distance and ensure the provision of healthcare services. this study aims to investigate the effects of conducting outpatient clinic visits remotely, for patients living with insulin pumps.

telemedicine also has the potential to be a cost-effective solution due to reductions in travelling costs and saved working days, as well as increased patient satisfaction due to the reduction in transportation time. several studies have evaluated telemedicine for use in diabetes mellitus patients with an insulin pump. in all of these studies, the telemedicine group scheduled more contacts with the health care professionals than in the standard care group. to the investigator's knowledge, no one has investigated telemedicine, compared to standard care with the same number of scheduled contacts. the investigators believe telemedicine should increase the level of service and not increase the workload for health care professionals. a telemedical solution can provide patients with a more flexible alternative for visiting their health care provider rather having the burden of extra telemedicine appointments plus regular treatment. patients in rural denmark may have a travelling time of 70 km (1 hour by car or several hours by public transport) to a specialised diabetes mellitus specialist centre. this may result in some patients choosing not to start or not being offered insulin pump treatment despite indications that an insulin pump is an optimal treatment choice. the challenge of distance also poses problems for patients in relation to technical problems or medical issues with the insulin pump. telemedicine should be a solution for both patients and their health care providers. in this randomised controlled study, the effects of conducting clinical visits remotely, for patients living with insulin pumps will be investigated. participants will be allocated to either intervention (standard care provide by video consultations) or standard care.

Eligibility criteria:
inclusion criteria: * adult patients over 18 years of age * diagnosed with diabetes type 1 * patient has used insulin pump for at least 6 months exclusion criteria: * no internet access * unable to adhere to protocol. * unable to speak or read danish.
neoadjuvant apalutamide (arn509) and radical prostatectomy in treatment of intermediate to high risk prostate cancer

Conditions: Cancer of the Prostate

Summary: this is an investigator-initiated phase ii single arm trial, combining neoadjuvant apalutamide (arn509) with radical prostatectomy, in the treatment of d'amico intermediate to high risk organ-confined prostate cancer. apalutamide has shown efficacy in castrate resistant prostate cancer in phase ii studies and are now in phase iii trials combined with radiation in organ confined disease. the primary study objectives include assessment of (i) oncological efficacy as determined by tumour downstaging and achievement of nadir psa the secondary study objectives include(i) determination of adverse effects related to apalutamide and surgical complication rates (ii) human prostate tissue effect of apalutamide the study will recruit thirty eligible participants who will receive 12 weeks of oral apalutamide 240mg daily. this will be followed by standard-of-care radical prostatectomy. the total trial duration is 26 weeks.

this is a phase ii single arm study looking at the efficacy of 12 weeks of neoadjuvant apalutamide (arn 509), combined with standard-of-care radical prostatectomy, for d'amico intermediate to high risk prostate cancer patients. the phases of the study will include: screening, treatment and follow-up phases. safety will be monitored throughout the study.

Eligibility criteria:
inclusion criteria: * histologically diagnosed primary adenocarcinoma of the prostate gland * non-metastatic d'amico intermediate to high risk patients undergoing radical prostatectomy as primary definitive therapy * no known hypersensitivity to the study drug * able to swallow study drug as whole tablets exclusion criteria: * presence of small cell, neuroendocrine or ductal differentiation at needle biopsy * individuals with prior pelvic irradiation therapy for any form of pelvic malignancy * patients with psychiatric conditions requiring anti-psychotic therapy, or preventing the provision of informed consent * renal impairment with serum creatinine more than twice the upper limit of normal * other prior malignancy less than or equal to 5 years prior to recruitment * ecog performance status 2 or poorer

Keywords: prostate cancer prostatectomy, retropubic androgen receptor antagonists
developing of a new incontinence care product

Conditions: Incontinence-associated Dermatitis; Nursing Care

Summary: the aim of this randomized controlled clinical trial, prospective study is to developing a new incontinece care product for containing the fecal incontinence and to examine the effect of this new product on prevention of perineal dermatitis.

urinary and faecal incontinence which affected the large number of people are common and embarrassing health problems. urinary incontinence affects the life quality , and causes to isolation and depression. faecal incontinence can cause to psychosocial problems such as loss of self-esteem, progressive isolation, social stigmatisation and reduces the life quality, also burden a high cost on the patients and the community . both urinary and fecal incontinence may leads to incontinence-associated dermatitis (iad), an inflamatory skin disease, which is a a clinical evolution of skin damage associated with moisture , as a result of chronic or repeated exposure of the skin to urine or fecal matter. in iad shows as redness with or without blistering, erosion, or loss of the skin barrier function iad which causes discomfort and stres for patients , is a serious and common problem in many health care setting and impacts patients' well-being. health care professionals who are working in many health institutions struggled to giving the optimal care to keep incontinent patients' skin in a healthy condition. when iad developed, the risk of infection, the length of hospitalization, and morbidity increases and those patients are at greater risk of developing a pressure ulser. the research question was; are there differences in the incidence of iad in patients with fecal incontinence by a new incontinece care versus adult diaper.

Eligibility criteria:
inclusion criteria: * bedridden patients who had fecal and urinary incontinence, * had not diabetes mellitus, * patients whose perineal and perianal skin is intact, * had indwelling urethral catheter and * patient who accepted to participate to the study exclusion criteria: * patients who had diabetes mellitus, * patients whose had darkly pigmented area in the perineal and perianal area, * patients had pressure ulcers or erithema * who have not accepted to participate

Keywords: fecal incontinence care product bowel incontinence
a long-term study of the safety of mk-0954a in patients with essential hypertension (mk-0954a-351)

Conditions: Hypertension

Summary: this study is being conducted to evaluate the safety of mk-0954a (l100/h12.5 mg) in essential hypertension participants who are uncontrolled with mk-954h (l50/h12.5 mg).


Eligibility criteria:
inclusion criteria: * participant has a diagnosis of essential hypertension. * participant is being treated with a single, or dual combination treatment for hypertension and will be able to discontinue the prior antihypertensive medication. * participant has a mean trough sidbp of \>=90mmhg and \< 110mmhg. * participant has a mean trough sisbp of \>=140mmhg and \< 200mmhg. * participant has no clinically significant abnormality at screening visit. exclusion criteria: * participant is currently taking \> 2 antihypertensive medications. * participant has a history of significant multiple and/or severe allergies to ingredients of nu-lotan or preminent and thiazide drug or related drug (i.e., sulfonamide-containing "chlortalidone" medicines). * participant is, at the time of signing informed consent, a user of recreational or illicit drugs or has had a recent history within the last year of drug or alcohol abuse or dependence. * participant is pregnant or breastfeeding, or expecting to conceive or the pregnancy test is positive at screening visit. * participant is currently participating or has participated in a study with an investigational compound or device within 30 days of signing informed consent.

Keywords: essential hypertension uncontrolled hypertension antihypertensive agents blood pressure
screening questionnaire for depression

Conditions: Depression

Summary: depression is common in primary care and general medical settings, but is often unrecognized and untreated by physicians working in those settings. the patient health questionnaire for depression (phq-9) is well validated and widely used screening instrument.


Eligibility criteria:
inclusion criteria: * \>18 yrs * primary care and general medical patients * understand the ic * speaks hebrew * no significant cognitive impairment

Keywords: depression screening primary care validity hebrew primary care and general medical patients
roll-over study to allow access to certinib (ldk378) for patients who are on ceritinib treatment in a novartis-sponsored study

Conditions: ALK Positive Malignancies

Summary: the rollover study will provide ceritinib to patients who are currently receiving treatment with ceritinib within a novartis-sponsored study and in the opinion of the investigator, would benefit from continued treatment with ceritinib.


Eligibility criteria:
inclusion criteria: * patient is currently receiving treatment with ceritinib within a novartis-sponsored study which has fulfilled the requirements for the primary objective and, in the opinion of the investigator, would benefit from continued treatment. * patient has demonstrated compliance, as assessed by the investigator, with the parent study protocol requirements. * willingness and ability to comply with scheduled visits, treatment plans and any other study procedures. * written informed consent obtained prior to enrolling in the roll-over study and receiving study medication. if consent cannot be expressed in writing, it must be formally documented and witnessed via an independent trusted witness. exclusion criteria: * patient has been permanently and prematurely discontinued from ceritinib study treatment in the parent study due to any reason. * patient currently has unresolved toxicities for which ceritinib dosing has been interrupted in the parent study. * pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive serum hcg laboratory test. * women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception during dosing and for 3 months afer stopping ceritinib treatment. * sexually active males unless they use a condom during intercourse while taking drug and for 3 months after stopping ceritinib and should not father a child for at least 3 months after the last dose of treatment.

Keywords: alk malignancies
covid-19 and sports - an online survey on the impact of the pandemic and possible preventive measures

Conditions: Covid19

Summary: aim of the study was to investigate the effects of the covid-19 pandemic on individual and general sport activities in an effort to provide information for safe return to community sports.


Eligibility criteria:
inclusion criteria: -age over 18 years exclusion criteria: * age under 18 years
response rate and side effects of preoperative chemotherapy (tox regimen) in patients with locally advanced operable gastric adenocarcinoma

Conditions: Gastric Cancer

Summary: early stage diagnosis of gastric cancer has ensued different approaches in its resection strategies. in order to increase the proportion of cases that undergo radical resection and reduce the recurrence rate, different pre-operative treatments are introduced. here, the investigators investigate an active preoperative chemotherapeutic regimen to in patients with locally advanced gastric cancer.


Eligibility criteria:
inclusion criteria: * tissue diagnosis of gastric or gastroesophageaql junction adenocarcinoma * t3, t4 any n with non metastatic condition * age 18 - 70 years * performance status 0,1 according to ecog criteria * adequate bone marrow , liver and renal function * hemoglobin ≥ 11 g/dl * platelets ≥ 100000 / mm3 * absolute neutrophil count ≥ 1500/mm3 * normal bilirubin * normal transaminases * normal creatinin * absence of active co-morbid illness (uncontrolled infection, uncontrolled dm, cardiopulmonary disease) exclusion criteria: * any metastatic disease, t1, t2, n0
comparison of nasal and forehead oximetry in critically ill patients at risk for decreased peripheral perfusion

Conditions: Hypotension; Pressure Ulcer

Summary: continuous pulse oximetry monitoring is the standard of care in critically ill patients in emergency departments, operating rooms and intensive care units. in patients with poor peripheral perfusion (low blood flow) due to peripheral vascular disease, low body temperature, or shock and the use of medications to raise the blood pressure, clinicians have difficulty obtaining an accurate measurement. this study compares the accuracy of forehead oximetry sensors to nasal alar sensors to lab oximetry measures and on the rate of device related pressure ulcers with both.

continuous pulse oximetry monitoring is the standard of care in critically ill patients in emergency departments, operating rooms and intensive care units. in patients with poor peripheral perfusion (low blood flow) due to peripheral vascular disease, low body temperature, or shock and the use of medications to raise the blood pressure, clinicians have difficulty obtaining an accurate measurement. several studies have demonstrated the utility of forehead sensor measurements under these clinical conditions. forehead sensor measurement is considered to be a more central measurement than with digit or ear sensors. however the sensor requires a head band for accurate measurement. on a regular basis, the forehead sensor has led to pressure ulcer development at barnes-jewish hospital despite following vendor recommendations for alternating placement every 8 hours from one side of the forehead to the other. an alternate sensor placed on the nose has recently demonstrated rapid detection of induced drops in oxygen saturation. it has also demonstrated correlation with arterial oxygen saturation measured in a clinical laboratory. the oxygen saturation measurement from the nose is also considered a central measurement. however, studies of the nose sensor were conducted in healthy subjects or during anesthesia care over several hours. therefore, research is needed to examine the accuracy of the nose sensor in the icu patient population. in addition, due to concerns for sensor related pressure ulcers in patients with decreased perfusion, the sensor needs to be evaluated for extended periods of time.

Eligibility criteria:
inclusion criteria: 1. presence of an existing arterial catheter for blood sampling and one of the following: 1. difficulty obtaining a consistent signal from a digit or ear sensor or 2. on pressors of at least 0 .10 mcg/kg/min of norepinephrine or 3. core temperature \< or equal to 35 degrees c exclusion criteria: 1. anatomic impediments (burns, wounds, dressings, etc.) to placement of the sensor on the forehead or nasal alar 2. history of known dyshemoglobinemias evidenced by carboxyhemoglobin levels \> 10% or methemoglobin level \> 2% 3. severe anemia with hemoglobin \< 5 g/dl 4. pregnant women